Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
The present invention provides isolated stabilized EPO-derived peptides and their mimics that protect against tissue damage in subjects having diverse forms of neural and non-neural organ system injury, pharmaceutical compositions containing the isolated stabilized EPO-derived peptides, methods for treating symptoms of a disease, disorder or condition having an inflammatory or an autoimmune component in a subject in need thereof, and methods for downregulating immune mediator activity in a subject in need thereof.
1. A method of treating symptoms of a disease, disorder or condition having an inflammatory or autoimmune component in a subject in need thereof, the method comprising the steps: (a) administering to the subject a therapeutically effective amount of a composition comprising at least one stabilized isolated EPO-derived peptide comprising an amino acid sequence comprising an N-terminal end and a C-terminal end and having a non-hematopoietic biological activity; and (b) maintaining the subject's red cell indices at substantially normal levels during treatment,
wherein the amino acid sequence of the stabilized isolated EPO-derived peptide is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 20, and SEQ ID NO: 30.
2. The method according to claim 1 , wherein the non-hematopoietic biological activity of the stabilized isolated EPO-derived peptide is stable when the peptide is stored at 4° C.
3. The method according to claim 1 , wherein the stabilized isolated EPO-derived peptide is stabilized by chemically adding a small bicyclic molecule to at least one of the N-terminal end or the C-terminal end of the peptide's amino acid sequence.
4. The method according to claim 1 , wherein the stabilized isolated EPO-derived peptide is stabilized by a disulfide bond formed between a sulfhydral group of a first amino acid residue and a sulfhydral group of a second amino acid residue along the peptide sequence.
5. The method according to claim 4 , wherein the stabilized isolated EPO-derived peptide comprises at least 6 amino acids having the peptide sequence XAEHYS (SEQ ID NO: 31), wherein X is a first amino acid residue containing a sulfhydral group and Y is a second amino acid residue containing a sulfhydral group, and wherein the sulfhydral group of the first amino acid residue is at an appropriate distance from the sulfhydral group of the second amino acid residue to form the disulfide bond with the sulfhydral group of the second amino acid residue within the peptide sequence, thus stabilizing the peptide.
6. The method according to claim 5 , wherein the stabilized isolated EPO-derived peptide is at least one peptide whose amino acid sequence is selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NO: 12, and SEQ ID NO: 15.
7. The method according to claim 4 , wherein the stabilized isolated EPO-derived peptide is further stabilized by chemically adding a small bicyclic molecule to at least one of the N-terminal end or the C-terminal end of the peptide's amino acid sequence.
8. The method according to claim 4 , wherein the stabilized isolated EPO-derived peptide is at least one peptide whose amino acid sequence is SEQ ID NO: 30.
9. The method according to claim 8 , wherein the stabilized isolated EPO-derived peptide is further stabilized by chemically adding a small bicyclic molecule to at least one of the N-terminal end or The C-terminal end of the peptide's amino acid sequence.
10. The method according to claim 9 , wherein the stabilized isolated EPO-derived peptide is at least one peptide whose amino acid sequence is SEQ ID NO: 20.
11. The method according to claim 1 , wherein when administered in a therapeutically effective amount to a subject in need thereof, the stabilized isolated EPO-derived peptide reduces clinical symptoms of at least one disease, disorder, or condition having an inflammatory or autoimmune component selected from the group consisting of an acute cerebrovascular injury, an acute spinal cord injury, an acute brain injury, an acute cardiovascular injury, an arthritis, an autoimmune disease, a demyelinating disease, and immune-mediated inflammation.
12. The method according to claim 1 , wherein the composition is administered by a route selected from the group consisting of orally, buccally, parenterally, nasally, rectally, and topically.
13. The method according to claim 1 , further comprising monitoring the subject's red blood cell indices.
14. The method according to claim 1 , wherein the stabilized isolated EPO-derived peptide is at least one peptide whose amino acid sequence is SEQ ID NO: 7.
15. The method according to claim 1 , wherein the stabilized isolated EPO-derived peptide is at least one peptide whose amino acid sequence is SEQ ID NO: 12.
16. The method according to claim 1 , wherein the stabilized isolated EPO-derived peptide is at least one peptide whose amino acid sequence is SEQ ID NO: 3.
17. A method of treating symptoms of a disease, disorder or condition having an inflammatory or autoimmune component in a subject in need thereof, the method comprising the steps: (a) administering to the subject a therapeutically effective amount of a composition comprising at least one stabilized isolated EPO-derived peptide comprising an amino acid sequence comprising an N-terminal end and a C-terminal end and having a non-hematopoietic biological activity; and (b) maintaining the subject's red cell indices at substantially normal levels during treatment,
wherein the amino acid sequence of the stabilized isolated EPO-derived peptide is selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 20, and SEQ ID NO: 30.
18. A method of treating symptoms of a disease, disorder or condition having an inflammatory or autoimmune component in a subject in need thereof, the method comprising the steps: (a) administering to the subject a therapeutically effective amount of a composition comprising at least one stabilized isolated EPO-derived peptide comprising an amino acid sequence comprising an N-terminal end and a C-terminal end and having a non-hematopoietic biological activity; and (b) maintaining the subject's red cell indices at substantially normal levels during treatment,
wherein the amino acid sequence of the stabilized isolated EPO-derived peptide is selected from the group consisting of SEQ ID NO: 7, SEQ ID NO: 3, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 20, and SEQ ID NO: 30.